Healthcare

Non-Invasive Prenatal Testing Market is Anticipated to Register an Exponential CAGR of 16% From 2019 to 2027

Transparency Market Research (TMR) has published a new report titled, “Non-Invasive Prenatal Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”.According to the report, the global non-invasive prenatal testing market was valued at US$ 1300 Mn in 2018. It is projected to expand at a CAGR of 16% from 2019 to 2027.Increasing cases of Downs’ syndrome, rising maternal age, and increasing demand for early and non-invasive fetal testing procedures are anticipated to boost the global non-invasive prenatal testing market from 2019 to 2027.Stringent regulatory guidelines, limitations of non-invasive prenatal testing, and availabilities of other alternatives would likely to hamper the growth of the global non-invasive prenatal testing market in the future.

  • Materni21 segment to hold prominent market share

Based on test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others.The MaterniT21 segment accounted for a significant share of the global non-invasive prenatal testing market in 2018. The segment is estimated to remain highly lucrative during the forecast period.

Request a Sample of Non-Invasive Prenatal Testing Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

In the U.S,, Sequenom (which was presently a part of Labcorp) introduced MateriT21 in 2011, which was the first NIPT solution in the U.S. MaterniT21 is able to identify trisomies and expanded tests may also explain sex chromosomes disabilities and some microdeletions. Less percentage error is a significant advantage of MaterniT21.

  • Market dominated by Laboratory Corporation of America Holdings and Roche

The report also provides profiles of leading players operating in the global non-invasive prenatal testing market. Product launch, strategic alliances, product promotions are the competitive business strategies for the major companies in order to sustain the global non-invasive prenatal testing market during the forecast period.

Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc, F. Hoffmann-La Roche Ltd, NATERA, INC., PerkinElmer Inc, Eurofins LifeCodexx AG, and IGENOMIX are major players operating in the global non-invasive prenatal testing market, offering products with proprietary technologies.

Tags

Related Articles

Close